BridgeBio Pharma, Inc. — Director's Dealing 2020

Nov 19, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-11-16

Reporting Person: YAU YI CHING (Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-16	Common Stock	M	5493	—	Acquired	6486	Direct
2020-11-16	Common Stock	F	1900	$44.33	Disposed	4586	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-16	Restricted Stock Units	$	M	399	Disposed		Common Stock (399)	Direct
2020-11-16	Restricted Stock Units	$	M	5094	Disposed		Common Stock (5094)	Direct

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 5,493 shares of Common Stock underlying the Reporting Person's RSUs.

F3: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.

F4: The RSUs vested as to 25% of the units on November 16, 2020 and as to 1/12th of the units each quarter thereafter for three additional years, subject to the Reporting Person's continuous service with the Issuer or any of its subsidiaries through each such vesting date, and have no expiration date.